乳腺癌治疗后高骨质疏松患病率及相关因素分析

目的探索乳腺癌治疗后患者的骨质疏松患病率及相关影响因素。方法回顾性分析147例治疗后并已绝经的乳腺癌患者的临床资料,采用双能X线骨密度吸收仪进行骨密度检测(包括腰椎正位L1~4、股骨颈以及全髋的骨密度测定),分析乳腺癌受体不同表达(ER、PR、HER-2)、年龄、体质量指数(bone mass index,BMI)、绝经时间、术后时间、治疗方法对骨质疏松的影响。结果147例乳腺癌患者治疗后的骨质疏松患病率为40.8%;单因素分析显示年龄、BMI、绝经时间、治疗(内分泌治疗+化疗)、术后时间与骨密度减低呈显著相关(P<0.05),多因素Logistic回归分析显示影响治疗后乳腺癌患者骨密度的主要因素是年龄、BMI、术后时间(P<0.05)。结论乳腺癌治疗后患者具有较高的骨质疏松患病率,乳腺癌治疗的多种因素都能够降低骨密度。

Analysis the high prevalence of osteoporosis and related factors in patients after treatment of breast cancer

Objective To explore the prevalence of osteoporosis and related factors after treatment of breast cancer. Methods Clinical data of 147 patients with breast cancer after treatment and menopause were collected and analyzed. Bone mineral density (BMD) of the lumbar spine, the left femoral neck, and total hip was detected using dual-energy X-ray absorptiometry. Breast cancer receptors (ER, PR, HER-2), age, BMI, menopause time, postoperative time, and treatment methods were analyzed. Results The prevalence of osteoporosis after treatment in 147 patients with breast cancer was 40.8%. Univariate analysis showed that age, BMI, menopause time, treatment (endocrine therapy + chemotherapy), postoperative time were significantly correlated with the decrease of BMD (P<0.05). Multivariate logistic regression analysis showed that age, BMI and postoperative time were the main influencing factors of BMD reduction (P<0.05). Conclusion The prevalence of osteoporosis is high in breast cancer patients. Many factors in breast cancer treatment can reduce BMD.